Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

For the past 7 years, Bayer has shelled out billions of dollars in lawsuits brought by people claiming they developed cancer after exposure to its glyphosate-containing weed killers, including its ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential.

On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.